AbbVie Inc. (ABBV) |
|
135.87 2.35 (1.76%)
|
01-16 05:09 |
|
Open: |
133.35 |
Pre. Close: |
133.52 |
|
High:
|
136.05 |
Low:
|
132.2906 |
|
Volume:
|
10,374,310 |
Market Cap:
|
240,202M |
|
|
|
|
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
136.204 - 136.745 |
136.745 - 137.211 |
|
Low:
|
130.804 - 131.467 |
131.467 - 132.039 |
|
Close:
|
134.711 - 135.806 |
135.806 - 136.749 |
|
Technical analysis |
as of: 2022-01-15 8:44:05 PM |
|
Overall:
|
  |
| Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 161.36 One year: 188.47 |
| Support: |
Support1: 129.23 Support2: 123.72 |
| Resistance: |
Resistance1: 138.15 Resistance2: 161.36 |
| Pivot: |
135.47 |
| Moving Average: |
MA(5): 136.01 MA(20): 134.38
MA(100): 117.90 MA(250): 114.19 |
| MACD: |
MACD(12,26): 3.03  Signal(9): 3.60 |
| Stochastic oscillator: |
%K(14,3): 57.80 %D(3): 70.16 |
| RSI: |
RSI(14): 63.43 |
| 52-week: |
High: 138.15 Low: 101.81 Change(%): 22.1 |
| Average Vol(K): |
3-Month: 639982 10-Days: 765719 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed above its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and BULLISH in mid-long term.ABBV has closed below upper band by 39.6%. Bollinger Bands are 61.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to ABBV's normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Headline News |
Fri, 14 Jan 2022
AbbVie Inc (ABBV) has fallen -1.48% in a Week, Should You Sell? - InvestorsObserver
Tue, 11 Jan 2022
AbbVie Inc. (ABBV) Management Presents at JPMorgan 40th Annual Healthcare Conference (Transcript) - Seeking Alpha
Mon, 10 Jan 2022
AbbVie (ABBV) Seeks Rinvoq Nod for Non-Radiographic AS - Entrepreneur
Sat, 08 Jan 2022
Just Four Days Till AbbVie Inc. (NYSE:ABBV) Will Be Trading Ex-Dividend - Nasdaq
Fri, 07 Jan 2022
Zacks Investment Ideas feature highlights: AbbVie, Inc. and Pfizer Inc - Yahoo Finance
Thu, 06 Jan 2022
AbbVie: Doing The RIG(HT) Thing - Seeking Alpha
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
|
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
|
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
|
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Neutral |
Price to Earnings: |
Outperform |
| Return on Equity: |
Outperform |
Debt to Equity: |
Outperform |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NYSE |
| Sector: Healthcare |
| Industry: Drug Manufacturers—General |
| Shares Out. (M) |
1,770 |
| Shares Float (M) |
1,750 |
|
% Held by Insiders
|
0.12 |
|
% Held by Institutions
|
68.22 |
|
Shares Short (K)
|
16,610 |
|
Shares Short P. Month (K)
|
14,120 |
Stock Financials |
|
EPS
|
4.200 |
|
EPS Est This Year
|
5.530 |
|
EPS Est Next Year
|
6.560 |
|
Book Value (p.s.)
|
7.660 |
|
Profit Margin
|
13.66 |
|
Operating Margin
|
36.70 |
|
Return on Assets (ttm)
|
8.5 |
|
Return on Equity (ttm)
|
52.3 |
|
Qtrly Rev. Growth
|
11.2 |
|
Gross Profit (p.s.)
|
17.938 |
|
Sales Per Share
|
31.169 |
|
EBITDA (p.s.)
|
16.299 |
|
Qtrly Earnings Growth
|
37.70 |
|
Operating Cash Flow (M)
|
22,560 |
|
Levered Free Cash Flow (M)
|
20,340 |
Stock Valuations |
|
PE Ratio
|
32.35 |
|
PEG Ratio
|
|
|
Price to Book value
|
17.74 |
|
Price to Sales
|
4.36 |
|
Price to Cash Flow
|
10.66 |
Stock Dividends |
|
Dividend
|
5.200 |
|
Forward Dividend
|
5.640 |
|
Dividend Yield
|
0.04 |
|
Dividend Pay Date
|
2022-02-14 |
|
Ex-Dividend Date
|
2022-01-12 |
|
7 Binary Options
|
|
Your Ad Here
|
|
